Search - tctmd.com

Displaying 21 - 40 of 393

Sort: Relevancy | Date

News Conference News CRT 2024

Mixed Bag With DCBs for In-Stent Restenosis, Small Coronary Arteries

L.A. McKeown

March 14, 2024

News Conference News CRT 2024

Full AGENT IDE Results Affirm Benefits of DCB for In-Stent Restenosis

L.A. McKeown

March 09, 2024

News Daily News

Agent Coronary DCB Gets FDA Approval for In-Stent Restenosis

L.A. McKeown

March 01, 2024

Presentation Miami Valves 2024

Multicenter Randomized Trial Comparing the AGENT Paclitaxel-Coated Balloon With Conventional Balloon Angioplasty for In-Stent Restenosis

Presenter: Thomas E. Noel

February 01, 2024

News Daily News

Top Endovascular News of 2023

L.A. McKeown

December 28, 2023

News Conference News TCT 2023

Sirolimus- and Paclitaxel-Coated Balloons Well-Matched for In-Stent Restenosis

Todd Neale

November 02, 2023

News Conference News TCT 2023

Comparing DCBs in De Novo CAD: Drugs, Design Matter

Caitlin E. Cox

October 25, 2023

News Conference News TCT 2023

‘Light at the End of the Tunnel’ for In-Stent Restenosis: AGENT IDE Wins Big

Todd Neale

October 25, 2023

News Conference News LINC 2023

PROSPECT MONSTER: Real-World Data Confirm Low-Dose DCB Efficacy in PAD

L.A. McKeown

June 21, 2023

News Industry News

Concept Medical’s fourth IDE approval for the MagicTouch Sirolimus Coated Balloon is granted for the treatment of Superficial Femoral Artery Disease (SFA)

June 01, 2023

News Daily News

Long-term Data Support Paclitaxel-Coated Balloons for In-Stent Restenosis

Michael O'Riordan

February 24, 2023

News Conference News AHA 2022

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

L.A. McKeown

November 07, 2022

News Conference News VIVA 2022

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

L.A. McKeown

November 03, 2022

News Industry News

TRANSFORM 1 Enrollment Completed: A Crucial RCT ready to redefine the DCB Angioplasty Mechanism

September 13, 2022

News Daily News

IVUS Useful in Many Peripheral Intervention Scenarios, Consensus Document

L.A. McKeown

August 05, 2022

News Daily News

Five-Year Paclitaxel DCB Data Attest to Long-term Safety, Efficacy

L.A. McKeown

June 01, 2022

News Conference News SCAI 2022

SAFE-PAD Provides More Long-term Safety Data for Paclitaxel

L.A. McKeown

May 22, 2022

Presentation ARCH 2022

Paclitaxel or Limus: What is the Future in Drug Eluting Therapies?

Presenter: Craig M. Walker

April 23, 2022

Presentation ACC 2022

A Randomized Trial To Confirm The Safety And Effectiveness Of Chocolate Touch Paclitaxel Coated PTA Balloon Catheter In Above The Knee Lesions

Presenter: Alexandra Lansky

April 04, 2022

News Conference News ACC 2022

Second-Generation Chocolate Touch DCB Bests Lutonix for Patency in PAD

L.A. McKeown

April 04, 2022

Advertisement

Mixed Bag With DCBs for In-Stent Restenosis, Small Coronary Arteries

Full AGENT IDE Results Affirm Benefits of DCB for In-Stent Restenosis

Agent Coronary DCB Gets FDA Approval for In-Stent Restenosis

Multicenter Randomized Trial Comparing the AGENT Paclitaxel-Coated Balloon With Conventional Balloon Angioplasty for In-Stent Restenosis

Top Endovascular News of 2023

Sirolimus- and Paclitaxel-Coated Balloons Well-Matched for In-Stent Restenosis

Comparing DCBs in De Novo CAD: Drugs, Design Matter

‘Light at the End of the Tunnel’ for In-Stent Restenosis: AGENT IDE Wins Big

PROSPECT MONSTER: Real-World Data Confirm Low-Dose DCB Efficacy in PAD

Concept Medical’s fourth IDE approval for the MagicTouch Sirolimus Coated Balloon is granted for the treatment of Superficial Femoral Artery Disease (SFA)

Long-term Data Support Paclitaxel-Coated Balloons for In-Stent Restenosis

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

TRANSFORM 1 Enrollment Completed: A Crucial RCT ready to redefine the DCB Angioplasty Mechanism

IVUS Useful in Many Peripheral Intervention Scenarios, Consensus Document

Five-Year Paclitaxel DCB Data Attest to Long-term Safety, Efficacy

SAFE-PAD Provides More Long-term Safety Data for Paclitaxel

Paclitaxel or Limus: What is the Future in Drug Eluting Therapies?

A Randomized Trial To Confirm The Safety And Effectiveness Of Chocolate Touch Paclitaxel Coated PTA Balloon Catheter In Above The Knee Lesions

Second-Generation Chocolate Touch DCB Bests Lutonix for Patency in PAD

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content